SHENZHEN, China--(BUSINESS WIRE)--Tongjitang Chinese Medicines Company (NYSE: TCM), a leading specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicines in China, today announced that it has filed a lawsuit against Jilin Liaoyuan Yulongyadong Pharmaceutical (“Yulongyadong”) for violation of PRC Intellectual Property (“IP”) Protection laws. The action, filed on May 28, 2008 in Guiyang Intermediate People’s Court in China, seeks to prevent Yulongyadong from infringing upon the Company’s trademark by deliberately copying its product, Xianling Gubao.
